Despite the promising prospects of MDM2-based PROTACs in inducing apoptosis in p53 wild-type tumor cells, challenges such as complex synthesis, high molecular weight, and lipophilicity continue to impede their broader development.27 This evidence concerns the gene MDM2 and neoplasm.